Équilibre Biopharmaceuticals
Ms. Dodge is Senior Vice President of Corporate Strategy and Investor Relations at Équilibre Biopharmaceutical Corp. Ms. Dodge oversees strategic planning, policy development and corporate engagements as well as spearheads strategic projects and initiatives that drive and deliver company priorities. Prior to joining Équilibre, Ms. Dodge was a principal at Indigo 8 Advisors.
Prior to co-founding Indigo 8 Advisors, Ms. Dodge was a Senior Vice President at Goldman Sachs & Co., and then held a leadership role at Morgan Stanley where she developed and led a team focused on values-based objectives.
Ms. Dodge is a graduate of Colby College after which she attended Syracuse University College of Law and New York University School of Law for her J.D. and LLM. Ms. Dodge is Board Member of The Art Therapy Project, a member of the American and New York Bar Associations, Volunteer Lawyers for the Arts and is a Sponsor Students Sponsor Partners. Ms. Dodge also serves on the Advisory Council for Kent School.
This person is not in any offices
Équilibre Biopharmaceuticals
Équilibre Biopharmaceuticals Corp. was established as an innovative biopharmaceutical company focused on identifying and developing high-potential drugs for patients who are treatment-resistant or unresponsive to other existing medications.